Allesandro Riva, MD

Articles by Allesandro Riva, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,Michael Smylie, MD,John R. Mackey, MD,Dick Au, MD,Evelyn Sansregret, MD,Daniel Noel, MD,Alexander H. Paterson, MD,Taher Al-tweigeri, MD,Fernad Delorme, MD,Allesandro Riva, MD

August 1st 1997

Preliminary results from phase I trials suggest that the use of docetaxel (Taxotere) and doxorubicin (Adriamycin) is a well tolerated and highly active combination regimen for

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,B. Thuerlimann, MD,W. R. Bezwoda, MD,D. Melnychuk, MD,L. Deschênes, MD,J. Douma, MD,T. A. Vandenberg, MD,B. Rapoport, MD,R. Rosso, MD,V. Trillet-lenoir, MD,J. Drbal, MD,Matti S. Aapro, MD,M. Alaki, MD,M. Murawsky, MD,Allesandro Riva, MD

August 1st 1997

This nonblinded, multicenter, randomized phase III study compares the median time to progression (primary endpoint), response rate, and quality of life, safety, and survival of

Latest Updated Articles

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer
August 1st 1997
Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer
August 1st 1997

Allesandro Riva, MD

Articles by Allesandro Riva, MD

Docetaxel/Doxorubicin/Cyclophosphamide in the Treatment of Metastatic Breast Cancer

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer

NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing

Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup

Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial

Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview